ESTRO 2022 - Abstract Book

TUESDAY 10 MAY 2022

Teaching Lecture Toxicity vs tumour control: What makes a good plan?........................................................................................... (abs. 954) How can omics lead to personalised radiation oncology?..................................................................................... (abs. 956) Is endometrial cancer ready for treatment individualisation based on molecular risk factors?........................ (abs. 957) Hypofractionation for the management of postoperative PCa............................................................................. (abs. 958) Deformable registration for dose accumulation: Current status and future challenges.................................... (abs. 959) Immunotherapy and radiotherapy: Basics for physicists....................................................................................... (abs. 960) Calculating margins correctly: Abracadabra with numbers?. .......................................................................(abs. 961 - 962) Symposium Anal cancer.........................................................................................................................................................(abs. 963 - 968) Joint Symposium ESTRO-ESR: Imaging biomarkers for personalised radiotherapy.................................................................(abs. 969 - 972) ESTRO-ESGO: Joint guidelines on the management of vaginal cancer. .......................................................(abs. 973 - 976) Symposium Fractionation for external beam radiation therapy in early breast cancer: State-of-the-art.....................(abs. 977 - 979) Medical physicists should be directly involved in the design, execution and interpretation of clinical trials. .................................................................................................................(abs. 980 - 983) Modelling of complex systems and interactions............................................................................................(abs. 984 - 986) Symposium Changes in disease pattern after the pandemic. ...........................................................................................(abs. 995 - 998) Adaptation and automation: The new frontier in radiotherapy................................................................ (abs. 999 - 1001) HPV-related squamous cell carcinoma: Is it time for de-intensification?. .............................................. (abs. 1002 - 1005) Debate This house believes that short-course radiotherapy is the ideal schedule as part of total neoadjuvant therapy programs for rectal cancer........................................................................ (abs. 1006 - 1011) Symposium Spatial and spatio-temporal fractionation................................................................................................. (abs. 1012 - 1014) Modelling at the voxel level: Dose and image-data mining. .................................................................... (abs. 1015 - 1018) Changing the radiation medicine paradigm.............................................................................................. (abs. 1019 - 1021) Pitch Session Closing Session: Which innovations will have the greatest impact in radiotherapy by 2030?.............. (abs. 1022 - 1027)